“Big money” Positions
“Big money sentiment for Pfizer Inc (NYSE:PFE) in Q4 2018 decreased to 0.74, according to SEC.gov filings. That’s down -0.11, from 2018Q3’s 0.85. 618 funds increased and opened new positions, while 834 sold and decreased their holdings in Pfizer Inc so the sentiment has dropped. Funds own 4.05 billion shares, up from 3.96 billion shares in 2018Q3. Funds holding Pfizer Inc in top 10 changed to 227 from 187 for an increase of 40. 42 Investors Sold All; 792 Reduced Holdings; 477 increased stakes while 141 funds bought stakes.
Most Pfizer Inc Investors
As of Q4 2018 Northeast Financial Consultants Inc has 14.68% invested in Pfizer Inc. As of Q4 2018, 18.35 million shares of Pfizer Inc are owned by Amundi Pioneer Asset Management Inc. In addition, Cincinnati Casualty Co reported 236,400 shares in Pfizer Inc equivalent to 9.58% of its fund’s portfolio. Stuyvesant Capital Management revealed 74,720 shares position in Pfizer Inc. The New York-based fund Knott David M holds 363,778 shares or 7.46% of their fund’s portfolio.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide.The firm is valued at $248.97 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH).The P/E ratio is 23.08. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
The stock decreased 0.67% or $0.29 during the last trading session, reaching $43.07.Currently Pfizer Inc. is uptrending after 20.88% change in last March 5, 2018. PFE has also 21.64 million shares volume. The stock outperformed the S&P 500 by 16.51%.
Pfizer Inc. (NYSE:PFE) is expected to announce earnings on May, 7., Faxor reports. This year’s earnings per share analyst estimate is expected to be $0.77. That is 0.00 % compareed to $0.77 earnings per share for last year. If the current earnings per share of $0.77 is accurate, PFE’s profit could be $4.45B. 20.31 % EPS growth is what analysts predict. $0.64 earnings per share was revealed for last quarter.
Confluence Inv Management Limited Liability invested in 2.37M shs. Hartline Inv Corp has invested 0.07% in Pfizer Inc. (NYSE:PFE). Axa reported 2.20M shs. Moreover, Plante Moran Financial Advsrs has 0.44% invested in Pfizer Inc. (NYSE:PFE) for 28,734 shs. Quantum Cap Mngmt stated it has 20,104 shs or 0.51% of all its holdings. Missouri-based Buckingham Asset Management Ltd has invested 0.59% in Pfizer Inc. (NYSE:PFE). Bancorporation Of Montreal Can invested in 0.79% or 19.25 million shs. Moreover, Mgmt Professionals Inc has 0.33% invested in Pfizer Inc. (NYSE:PFE). Columbia Asset Management has invested 1.39% of its capital in Pfizer Inc. (NYSE:PFE). The New Jersey-based Hamel has invested 0.61% in Pfizer Inc. (NYSE:PFE). 62,336 are held by Winslow Evans And Crocker. Victory Cap Management owns 0.09% invested in Pfizer Inc. (NYSE:PFE) for 818,759 shs. Mutual Of America Mgmt Lc invested 0.55% in Pfizer Inc. (NYSE:PFE). Baxter Bros Inc stated it has 17,738 shs or 0.21% of all its holdings. Wealth Enhancement Advisory Services Limited owns 0.27% invested in Pfizer Inc. (NYSE:PFE) for 102,273 shs.
Pfizer Inc. registered $1.81 million net activity with 0 insider buys and 1 insider sale since January 30, 2019.
Pfizer Inc. (NYSE:PFE) Ratings Coverage
In total 6 analysts cover Pfizer (NYSE:PFE). “Buy” rating has 3, “Sell” are 0, while 3 are “Hold”. 50% are bullish. 10 are the (NYSE:PFE)’s analyst reports since October 31, 2018 according to StockzIntelligence Inc. On Thursday, November 1 the firm has “Market Perform” rating given by BMO Capital Markets. On Tuesday, November 6 the rating was maintained by Citigroup with “Sell”. On Thursday, January 31 the firm earned “Outperform” rating by Argus Research. In Tuesday, December 11 report JP Morgan downgraded the stock to “Neutral” rating. In Wednesday, January 23 report UBS downgraded the stock to “Neutral” rating. In Thursday, January 31 report Credit Suisse upgraded the stock to “Outperform” rating. On Monday, February 25 the stock has “Hold” rating by UBS. On Wednesday, October 31 the company was maintained by Credit Suisse. On Tuesday, February 19 the firm has “Buy” rating by Cantor Fitzgerald given.
For more Pfizer Inc. (NYSE:PFE) news posted briefly go to: Seekingalpha.com, Fool.com, Seekingalpha.com, Streetinsider.com or Fool.com. The titles are as follows: “Pfizer recalls contaminated high blood pressure drug in Japan – Seeking Alpha” posted on February 08, 2019, “Why Sangamo Therapeutics Lost 22.9% of Its Value in February – Motley Fool” on March 04, 2019, “Pfizer Biopharmaceuticals Group’s Late-Stage Pipeline Looks Well Positioned – Seeking Alpha” with a publish date: February 06, 2019, “Pfizer Inc. (PFE) and Astellas Announce Phase 3 ARCHES Trial Shows XTANDI Significantly Improved Radiographic PFS in Men with Metastatic Hormone-Sensitive Prostate Cancer – StreetInsider.com” and the last “Here’s Why Ascendis Pharma Is Rocketing Higher Today – Motley Fool” with publication date: March 04, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.